Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 47,463,272
  • Shares Outstanding, K 132,114
  • Annual Sales, $ 2,248 M
  • Annual Income, $ -278,160 K
  • EBIT $ 265 M
  • EBITDA $ 321 M
  • 60-Month Beta 0.32
  • Price/Sales 14.87
  • Price/Cash Flow N/A
  • Price/Book 207.22

Options Overview Details

View History
  • Implied Volatility 44.29% (+0.63%)
  • Historical Volatility 38.54%
  • IV Percentile 65%
  • IV Rank 38.31%
  • IV High 68.01% on 04/08/25
  • IV Low 29.56% on 08/13/25
  • Expected Move (DTE 35) 35.19 (9.79%)
  • Put/Call Vol Ratio 1.40
  • Today's Volume 1,057
  • Volume Avg (30-Day) 1,019
  • Put/Call OI Ratio 0.50
  • Today's Open Interest 32,710
  • Open Int (30-Day) 30,224
  • Expected Range 324.08 to 394.46

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.81
  • Number of Estimates 11
  • High Estimate 2.53
  • Low Estimate -0.63
  • Prior Year -0.65
  • Growth Rate Est. (year over year) +224.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
353.52 +1.63%
on 01/12/26
427.05 -15.87%
on 01/07/26
-31.90 (-8.16%)
since 12/16/25
3-Month
353.52 +1.63%
on 01/12/26
495.55 -27.50%
on 10/20/25
-121.80 (-25.32%)
since 10/16/25
52-Week
205.87 +74.51%
on 04/09/25
495.55 -27.50%
on 10/20/25
+110.11 (+44.19%)
since 01/16/25

Most Recent Stories

More News
Stocks Recover as Data Storage Companies and Chip Makers Rally

The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +0.16%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.17%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.08%. March E-mini S&P...

AMAT : 327.01 (+2.49%)
B : 48.73 (-1.83%)
AVGO : 351.71 (+2.53%)
C : 118.04 (+0.49%)
HL : 26.54 (+5.23%)
HSIC : 79.98 (+2.43%)
CDE : 22.58 (+6.41%)
JPM : 312.47 (+1.04%)
AKAM : 93.49 (+2.14%)
ANIP : 84.83 (-0.54%)
$IUXX : 25,529.26 (-0.07%)
UNH : 331.02 (-2.34%)
Equity Indexes Recover Early Losses as Precious Metals Reach New Record Highs

The S&P 500 Index ($SPX ) (SPY ) today is up +0.28%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.15%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.55%. After opening lower, stock indexes...

B : 48.73 (-1.83%)
C : 118.04 (+0.49%)
HL : 26.54 (+5.23%)
HSIC : 79.98 (+2.43%)
CDE : 22.58 (+6.41%)
JPM : 312.47 (+1.04%)
AKAM : 93.49 (+2.14%)
ANIP : 84.83 (-0.54%)
$IUXX : 25,529.26 (-0.07%)
UNH : 331.02 (-2.34%)
ZNH26 : 111-240s (-0.42%)
MA : 539.49 (-0.58%)
Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact

− Full Year 2025 Preliminary* Net Product Revenues of $2,987 Million (81% Growth vs. 2024), Driven Primarily by Preliminary* Total TTR Revenues of $2,487 Million (103% Growth vs. 2024) – ...

ALNY : 359.27 (unch)
Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview and participate in a Q&A session at the 44 ...

ALNY : 359.27 (unch)
Stocks Slip as Bond Yields Rise

The S&P 500 Index ($SPX ) (SPY ) today is down -0.12%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.25%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.11%. March E-mini S&P futures...

C : 118.04 (+0.49%)
RARE : 22.49 (-4.30%)
SLB : 46.73 (+0.34%)
$IUXX : 25,529.26 (-0.07%)
ZNH26 : 111-240s (-0.42%)
OXY : 42.70 (-1.09%)
ESH26 : 6,976.75s (-0.07%)
FANG : 151.28 (+0.30%)
$DOWI : 49,359.33 (-0.17%)
SPY : 691.66 (-0.08%)
DIA : 493.42 (-0.21%)
INSM : 161.42 (+1.35%)
Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics

New platform is expected to substantially increase manufacturing capacity and lower production costs, enabling investment in expanding pipeline FDA has accepted Alnylam’s enzymatic ligation...

ALNY : 359.27 (unch)
Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027

Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has entered into separate, privately negotiated repurchase agreements with certain...

ALNY : 359.27 (unch)
Alnylam Pharmaceuticals Announces Changes to Board of Directors

– Mike Bonney and Carolyn Bertozzi to Depart; Company Appoints Stuart Arbuckle as New Independent Director –

ALNY : 359.27 (unch)
Is Vertex Pharmaceuticals Stock Underperforming the Nasdaq?

Vertex Pharmaceuticals has underperformed the broader Nasdaq index over the past year. However, Wall Street analysts remain moderately optimistic about its prospects.

$NASX : 23,515.39 (-0.06%)
VRTX : 441.36 (+0.56%)
ALNY : 359.27 (unch)
The Biotech Boom Gets a Trading Tool: How Direxion's Titans ETF Gives Access to the Sector's Top Performers

Amid the biotechnology sector's transformative era the Direxion Daily Biotech Top 5 Bull 2X ETF ($TBXU) offers traders a new, single-trade solution to gain 2X daily leveraged exposure to an e

ALNY : 359.27 (unch)
EXEL : 43.96 (-3.26%)
GILD : 124.91 (+3.01%)
INSM : 161.42 (+1.35%)
UTHR : 464.93 (-1.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

Relative Strength is below 30%. The market is in oversold territory. Watch for a potential trend reversal.

See More Share

Business Summary

Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference. The company's pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas - genetic medicines, cardio-metabolic...

See More

Key Turning Points

3rd Resistance Point 377.57
2nd Resistance Point 372.38
1st Resistance Point 365.83
Last Price 359.27
1st Support Level 354.09
2nd Support Level 348.90
3rd Support Level 342.35

See More

52-Week High 495.55
Fibonacci 61.8% 384.89
Last Price 359.27
Fibonacci 50% 350.71
Fibonacci 38.2% 316.53
52-Week Low 205.87

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar